These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38609824)

  • 1. Good response of cadonilimab (PD-1/CTLA-4 bi-specific antibody) to patients with advanced lung adenocarcinoma after immunotherapy resistance: A case report.
    An E; Lu J; Chen L
    Asian J Surg; 2024 Jul; 47(7):3348-3349. PubMed ID: 38609824
    [No Abstract]   [Full Text] [Related]  

  • 2. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report.
    Wu N; Yang X; Zhai Y; Lu W
    J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy rechallenge of advanced lung adenocarcinoma with cadonilimab (PD-1/CTLA-4 Bi-specific antibody): a case report.
    Wang X; Yang K; Yang Y; Wang X; Yuan K
    Anticancer Drugs; 2024 Mar; 35(3):288-291. PubMed ID: 37982205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer.
    Chen C; Chen M; Bai Y; Li Y; Peng J; Yao B; Feng J; Zhou JG; Ma H
    Technol Cancer Res Treat; 2024; 23():15330338241249690. PubMed ID: 38706247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
    Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
    [No Abstract]   [Full Text] [Related]  

  • 6. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
    Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A decade of immune-checkpoint inhibitors in cancer therapy.
    Robert C
    Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
    Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J
    Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.
    Yuan S; Hu X; Zhao Y; Wang Z
    Front Immunol; 2020; 11():563622. PubMed ID: 33240259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8
    Peng DH; Rodriguez BL; Diao L; Chen L; Wang J; Byers LA; Wei Y; Chapman HA; Yamauchi M; Behrens C; Raso G; Soto LMS; Cuentes ERP; Wistuba II; Kurie JM; Gibbons DL
    Nat Commun; 2020 Sep; 11(1):4520. PubMed ID: 32908154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
    Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
    Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of immunotherapy use and management of toxicities in regional and tertiary settings.
    Hamilton B; Xu K; Honeyball F; Balakrishnar B; Zielinski R
    Intern Med J; 2019 Aug; 49(8):1010-1015. PubMed ID: 30693623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
    Sakai T; Udagawa H; Matsumoto S; Yoh K; Nosaki K; Ikeda T; Zenke Y; Kirita K; Niho S; Akimoto T; Goto K; Ishii G
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1227-1237. PubMed ID: 32997195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of PD-L1 assessment in advanced NSCLC: does it still matter?
    Rizzo A; Dall'Olio FG; Altimari A; Giunchi F; Ardizzoni A
    Anticancer Drugs; 2021 Nov; 32(10):1084-1085. PubMed ID: 34232942
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
    Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.